Results 31 to 40 of about 6,338 (149)

A high-grade undifferentiated endometrial stromal sarcoma presenting as inversion of the uterus: A rare case

open access: yesJournal of Mid-Life Health, 2020
Endometrial stromal sarcoma (ESS) is a rare malignant tumor that constitutes about 0.2% of all uterine malignancies and 10% of uterine sarcomas. ESS is generally misdiagnosed as leiomyoma or endometrial polyp and typically discovered on histopathological
Nalini Sharma   +3 more
doaj   +1 more source

New Aspects of Sarcomas of Uterine Corpus—A Brief Narrative Review

open access: yesClinics and Practice, 2021
Sarcomas of the uterine corpus are rare malignant neoplasms, which are further classified into mesenchymal tumors, and mixed (epithelial plus mesenchymal) tumors.
Stoyan Kostov   +9 more
doaj   +1 more source

Disseminated Endometriosis and Low-Grade Endometrioid Stromal Sarcoma in a Patient with a History of Uterine Morcellation for Adenomyosis

open access: yesCase Reports in Obstetrics and Gynecology, 2020
Morcellation of benign uterine tumors allows for removal of the tumors via minimally invasive laparoscopic procedures. However, in rare cases, morcellation has been associated with upstaging of unexpected malignancies.
Daniel P. Stefanko   +2 more
doaj   +1 more source

Cancer‐associated mutations in endometriosis reframe a benign disease through molecular oncology

open access: yesMolecular Oncology, EarlyView.
This review aims to comprehensively analyse cancer‐associated somatic mutations (CAMs) present in endometriotic lesions, emphasizing their biological roles, spatial distribution and implications for translational applications in medicine. By contextualizing a benign state within a genomic framework, this analysis seeks to establish its value as a ...
Clarissa Mujacic   +15 more
wiley   +1 more source

Histopathology of Endometrial Stromal Sarcoma with Emphasis on Immunohistochemistry Marker Expression: Report of Three Cases

open access: yesMedical Journal of Dr. D.Y. Patil Vidyapeeth
Endometrial stromal tumors are rare uterine mesenchymal neoplasms. Endometrial stromal sarcomas (ESSs) are of endometrial stromal origin that accounts for approximately 1% of all uterine malignant neoplasms.
Narayanamoorthy Keerthyraj   +5 more
doaj   +1 more source

Low-grade endometrial stromal sarcoma: A report of five cases

open access: yesArchives of Medicine and Health Sciences, 2018
Endometrial stromal sarcoma (ESS) is a very rare uterine tumor, composed of cells resembling endometrial stromal cells. As these tumors have indistinct clinical and radiological features, they are very rarely diagnosed preoperatively.
Saba Bashir, Prema Saldanha
doaj   +1 more source

Characteristic of Endometrial Stromal Sarcoma by Algorithm of Potential Biomarkers for Uterine Mesenchymal Tumor

open access: yesCurrent Issues in Molecular Biology, 2023
The benign tumor uterine leiomyoma (UL) develops from the smooth muscle tissue that constitutes the uterus, whereas malignant tumor uterine sarcoma develops from either the smooth muscle tissue or stroma and is different from UL and endometrial cancer ...
Takuma Hayashi   +4 more
doaj   +1 more source

Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level

open access: yesAging and Cancer, EarlyView.
This graphical abstract illustrates the key biological pathways linking aging with cancer development and progression. In the upper left, cumulative exposure to ultraviolet radiation, toxins, and reactive oxygen species (ROS) causes DNA damage and genomic instability, whereas age‐related decline in repair mechanisms, such as ATM/ATR, BER, and NER ...
Anu Singh, Aroonima Misra, Sufian Zaheer
wiley   +1 more source

Low-grade endometrial stromal sarcoma in a postmenopausal woman with third-degree uterovaginal prolapse: A rare case with review of the literature

open access: yesJournal of Mid-Life Health, 2018
Endometrial stromal sarcomas (ESSs) are rare malignant tumors of the uterus that arise from the endometrial stroma, the annual incidence of ESS being 1–2/million women.
Meenakshi Gothwal   +4 more
doaj   +1 more source

The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies

open access: yesAdvanced Science, EarlyView.
This review elucidates how cancer cell metabolic reprogramming—across glucose, lipid, amino acid, and nucleotide pathways—remodels the tumor microenvironment to suppress anti‐tumor immunity and promote immune escape. Targeting these metabolic axes offers promising strategies to overcome immunotherapy resistance and enhance cancer treatment.
Guoqing Xiang   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy